 EXTON, Pa.--BUSINESS WIRE--Immunome, Inc. Nasdaq: IMNM, a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update. The fourth quarter of 2020 was a transformational period for Immunome thanks to our successful initial public offering on the NASDAQ exchange, which raised 